Company intelligence / Profile preview

PegaOne

Paris, France

Ownership: Private
Development stage: Other

Overview

PegaOne was a clinical-stage biopharmaceutical company focused on the development of targeted oncology therapies for solid tumors. The company's lead asset, PG-011, is a high-affinity monoclonal antibody targeting Claudin 18.2, a protein frequently overexpressed in gastric, gastroesophageal junction, and pancreatic cancers. In September 2021, PegaOne was acquired by Agenus to bolster its immuno-oncology pipeline and facilitate the development of combination therapies. The acquisition integrated PegaOne's Claudin 18.2 program into Agenus's broader portfolio of antibody-based treatments.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

imgatuzumab

Beyond the preview

Go deeper on PegaOne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PegaOne.

Explore the full profile